Number of variants called: 1.7 million

Polygenic risk scores are a way to estimate an individual’s genetic risk for a particular disease or trait based on multiple genetic variants across the genome. For cardiovascular disease (CVD), PRS can be calculated using genetic variants associated with various CVD risk factors such as blood pressure, cholesterol levels, and body mass index.

Historically, however, polygenic risk scores have been seen to have decreased accuracy among minority ethnic groups. This is because PRS are based on genetic variants that have been identified in large genome-wide association studies (GWAS) conducted primarily in populations of European ancestry. However, genetic variation can vary across populations, and some genetic variants that are important predictors of disease risk in one population may not be as informative in another population. This can lead to lower accuracy of PRS among non-European populations. There is often limited data available on non-European populations, which can make it difficult to identify genetic variants that are specific to these populations. This can result in the inclusion of less informative variants in PRS, leading to lower accuracy.

MetaGRS is a type of Cardiovascular Disease polygenic risk score that incorporates information from multiple studies and populations to increase its accuracy and generalizability. Specifically, metaGRS uses a statistical technique called meta-analysis to combine the results of multiple studies that have identified genetic variants associated with CVD risk. This approach helps to reduce the influence of any single study or population on the PRS calculation, and also allows for the inclusion of variants that may be specific to certain populations or subgroups.

Our MetaGRS Polygenic Risk score looks at 1.7 million variants across a patient’s genome, providing the most comprehensive and accurate polygenic risk score on the market.